Flex Pharma
As of the edition of 20 October 2026, Flex Pharma runs 2 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Flex Pharma was renamed in 2019.
- Flex Pharma, Inc.: renamed in 2019
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Nilotinib | Ends 2032 (patent) | 0 |
A route B row is one company at one target.
Where its trials are
- Nervous system: 4 trials led
- Nutrition and metabolism: 3 trials led
- Bones, joints and muscles: 2 trials led